← All trials
NCT05182658
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jul 31, 2023
- Completion date
- Aug 1, 2024
- First posted
- Jan 10, 2022
- Last posted
- Apr 12, 2022
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of WarsawLead sponsor
- Medical University of BialystokCollaborator
- Medical University of BialystokOverall official - principal investigator
- University of Eastern FinlandCollaborator
- Free University of AmsterdamCollaborator
- Medical University of BialystokOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.